幼年特发性关节炎患儿接种麻疹-腮腺炎-风疹减毒活疫苗加强免疫后的长期免疫保护
本研究在荷兰乌得勒支Wilhelmina儿童医院开展,分析182例接受免疫调节治疗的幼年特发性关节炎(JIA)患儿接种麻疹-腮腺炎-风疹(MMR)加强疫苗后的长期体液免疫保护。接种后5年,接种时使用生物制剂改善病情抗风湿药(bDMARD)的患者麻疹保护性抗体水平百分比显著低于未使用者(60% vs 86%,P=0.03);腮腺炎和风疹的差异未达统计学显著。作者认为多数JIA患儿有长期免疫原性,但bDMARD使用者麻疹保护性抗体百分比较低,或需在加强接种至少5年后检测抗体水平并据此建议额外加强接种。
要点
- 接种后5年,接种时使用bDMARD者麻疹保护性抗体百分比为60%,未使用者为86%(P=0.03)。
- 腮腺炎保护性抗体百分比bDMARD使用者80% vs 未使用者94%(P=0.11),风疹60% vs 83%(P=0.07),均未达统计学显著。
- 抗体水平随接种后时间下降,但bDMARD使用者与未使用者之间无显著差异。
核心结论
- MMR加强疫苗在多数JIA患儿中显示长期免疫原性,但bDMARD使用者麻疹保护性抗体百分比较低,作者认为或需在该组加强接种至少5年后检测抗体水平并据此建议额外加强接种。
研究设计与样本
- 研究在荷兰乌得勒支Wilhelmina儿童医院开展,纳入接种MMR加强疫苗时正在接受免疫调节治疗的JIA患者,采用化学发光微粒子免疫分析法(CMIA)检测储存血清样本中的MMR特异性IgG抗体浓度,并进行粗分析和校正分析。
- 共分析来自182例患者的236份样本,其中67份为接种后5年样本,另169份为末次随访访视样本,接种后中位时间为6.9年(IQR:2.8-8.8)。
- 28例患者使用bDMARD,其中96%为抗TNF药物,4%为托珠单抗。
主要发现
- 接种后5年,接种时使用bDMARD的患者麻疹保护性抗体水平百分比显著低于未使用者:60% vs 86%(P=0.03)。
- 腮腺炎保护性抗体水平百分比bDMARD使用者为80%,未使用者为94%(P=0.11),差异未达统计学显著。
- 风疹保护性抗体水平百分比bDMARD使用者为60%,未使用者为83%(P=0.07),差异未达统计学显著。
- 接种后抗体水平随时间下降,但bDMARD使用者与未使用者之间无显著差异。
临床怎么用
- 作者认为,对于接种MMR加强疫苗时使用bDMARD的JIA患者,或需在加强接种至少5年后检测抗体水平,并据此建议额外加强接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vaccines, especially live attenuated vaccines, in children with JIA pose a great challenge due to both potential lower immunogenicity and safety as a result of immunosuppressive treatment. For many years, in the Netherlands, JIA patients receive a measles-mumps-rubella (MMR) booster vaccine at the age of nine years as part of the national immunization program. OBJECTIVES: To study long-term humoral immunoprotection in a large cohort of JIA patients who received the MMR booster vaccine while being treated with immunomodulatory therapies at the Wilhelmina Children's Hospital in Utrecht, the Netherlands. METHODS: MMR-specific IgG antibody concentrations in stored serum samples of vaccinated JIA patients were determined with chemiluminescent microparticle immunoassays (CMIA). Samples were analyzed five years after MMR booster vaccination and at last available follow-up visit using both crude and adjusted analyses. Additional clinical data were collected from electronic medical records. RESULTS: In total, 236 samples from 182 patients were analyzed, including 67 samples that were available five years post-vaccination, and an additional 169 samples available from last visits with a median duration after vaccination of 6.9 years (IQR: 2.8-8.8). Twenty-eight patients were using biologic disease-modifying antirheumatic drugs (bDMARDS) of whom 96% anti-TNF agents and 4% tocilizumab. Percentages of protective antibody levels against measles after five years were significantly lower for patients who used bDMARD therapy at vaccination compared to patients who did not: 60% versus 86% (P = 0.03). For mumps (80% versus 94%) and rubella (60% versus 83%) this difference did not reach statistical significance (P = 0.11 and P = 0.07, respectively). Antibody levels post-vaccination decreased over time, albeit not significantly different between bDMARD users and non-bDMARD users. CONCLUSION: The MMR booster vaccine demonstrated long-term immunogenicity in the majority of children with JIA from a large cohort, although lower percentages of protective measles antibody levels were observed in bDMARD users. Hence, it might be indicated to measure antibody levels at least five years after MMR booster vaccination in the latter group and advice an extra booster accordingly.
引用
- Hamad Saied M, van Straalen JW, de Roock S, et al. Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis. Vaccine. 2023. PMID: 37516575. doi:10.1016/j.vaccine.2023.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。